The dual thromboxane receptor antagonist and thromboxane synthase inhibitor EV-077 is a more potent inhibitor of platelet function than aspirin

Journal of Thrombosis and Haemostasis

Volumn 9, Issue 10, 2011, Pages 2109-2111

  Fontana, P ^a   Alberts, P ^b   Sakariassen, K S ^c   Bounameaux, H ^a   Meyer, J P ^b   Santana Sorensen, A ^b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b EVOLVA SA   (Switzerland)

^c Kellsa SAS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; EV 077; THROMBOXANE A2; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; THROMBOXANE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; BINDING AFFINITY; DRUG POTENCY; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; IN VITRO STUDY; LETTER; MALE; NORMAL HUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

ASPIRIN; ENZYME INHIBITORS; HUMANS; PLATELET AGGREGATION INHIBITORS; RECEPTORS, THROMBOXANE; THROMBOXANE-A SYNTHASE;

EID: 80053408596     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2011.04446.x     Document Type: Letter

References (9)

1. Fontana P, Reny JL. New antiplatelet strategies in atherothrombosis and their indications. Eur J Vasc Endovasc Surg 2007; 34: 10-17.
2. Sakariassen KS, Alberts P, Fontana P, Mann J, Bounameaux H, Sorensen AS. Effect of pharmaceutical interventions targeting thromboxane receptors and thromboxane synthase in cardiovascular and renal diseases. Future Cardiol 2009; 5: 479-93.
3. Audoly LP, Rocca B, Fabre JE, Koller BH, Thomas D, Loeb AL, Coffman TM, FitzGerald GA. Cardiovascular responses to the isoprostanes iPF(2alpha)-III and iPE(2)-III are mediated via the thromboxane A(2) receptor in vivo. Circulation 2000; 101: 2833-40.
4. Borsch-Haubold AG, Pasquet S, Watson SP. Direct inhibition of cyclooxygenase-1 and -2 by the kinase inhibitors SB 203580 and PD 98059. SB 203580 also inhibits thromboxane synthase. J Biol Chem 1998; 273: 28766-72.
5. Sakariassen KS, Muggli R, Baumgartner HR. Measurements of platelet interaction with components of the vessel wall in flowing blood. Methods Enzymol 1989; 169: 37-70.
6. Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 1973; 22: 3099-108.
7. Reilly IA, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 1987; 69: 180-6.
8. Roger S, Pawlowski M, Habib A, Jandrot-Perrus M, Rosa JP, Bryckaert M. Costimulation of the Gi-coupled ADP receptor and the Gq-coupled TXA2 receptor is required for ERK2 activation in collagen-induced platelet aggregation. FEBS Lett 2004; 556: 227-35.
9. Cayatte AJ, Du Y, Oliver-Krasinski J, Lavielle G, Verbeuren TJ, Cohen RA. The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscler Thromb Vasc Biol 2000; 20: 1724-8.